Approval · Notice of Compliance 22194 · 2019
REACTINE COMPLETE: Notice of Compliance 22194
Issued May 24, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22194
- Date
- May 24, 2019
- Company
- McNeil Consumer Healthcare, division of Johnson & Johnson Inc.Markham, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling updates to comply with the plain language labelling regulations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE COMPLETE | Not yet assigned | — |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- PSEUDOEPHEDRINE HCL 120 MG per TAB